Moreover, the results indicated that 88/172 (51.16%, GRK5+/ACTC1+) of the cancer samples had moderate/strong staining and 84/172 (48.84%, others) had low/absent staining, while the IHC analysis of the 41 paratumor tissues indicated that 37/41 (90.24%, others) and low/absent staining and 4/41 (9.76%, GRK5+/ACTC1+) had moderate/strong staining. This evidence concerns the gene GRK5 and cancer.